Biostage, Inc. Common Stock
BSTG
BSTG was delisted on the 5th of October, 2017.
25 hedge funds and large institutions have $773K invested in Biostage, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
4% more funds holding
Funds holding: 24 → 25 (+1)
32% less capital invested
Capital invested by funds: $1.14M → $773K (-$370K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$59.6K |
| 2 |
VF
Virtu Financial
New York
|
+$28.3K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$8.29K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$5.36K |
| 5 |
Bank of New York Mellon
New York
|
+$3.88K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$197K |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$18.3K |
| 3 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$3K |
| 4 |
Morgan Stanley
New York
|
-$402 |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$401 |
BSTG Hedge Fund Activity: Q3 2017 in Review
25 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Biostage, Inc. Common Stock (BSTG) for Q3 2017, worth a combined $773K — down 32% from $1.14M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new BSTG positions and 2 closed out — a net gain of 2 holders — while 7 added to existing stakes and 4 trimmed.
The largest buyer was Vanguard Group, adding an estimated $59.6K. The largest seller was Renaissance Technologies, cutting an estimated $197K.
- 25 institutional investors held Biostage, Inc. Common Stock (BSTG) as of Q3 2017, up from 24 in Q2 2017.
- Funds reported $773K of Biostage, Inc. Common Stock stock for Q3 2017, down 32% quarter-over-quarter.
- 4 funds opened new Biostage, Inc. Common Stock positions in Q3 2017 and 2 closed out, a net change of +2 holders.
- The largest Biostage, Inc. Common Stock buyer in Q3 2017 was Vanguard Group, an estimated $59.6K added.
- The largest Biostage, Inc. Common Stock seller in Q3 2017 was Renaissance Technologies, an estimated $197K sold.
Based on aggregated 13F filings for Q3 2017.